Corporate News
Launching of ORALTEK in China
September 2023
INMUNOTEK has commenced operations in China with the launch of ORALTEK, a sublingual spray for allergen-specific immunotherapy. This follows the collaboration agreement with HOB-Biotech as partner for distribution and commercialization in China.
More info
New subsidiary in New Zealand
July 2023
INMUNOTEK establishes a new subsidiary in New Zealand. INMUNOTEK NEW ZEALAND LTD represents INMUNOTEK’s second subsidiary in Oceania and its eighth worldwide.
More info
New subsidiary in Australia
June 2023
INMUNOTEK establishes a new subsidiary in Australia. INMUNOTEK AUSTRALIA PTY LTD represents INMUNOTEK’s first subsidiary in Oceania and its seventh worldwide.
More info
Results with mannan-conjugated allergoids in EAACI
June 2023
The clinical results obtained with the new mannan-conjugated allergoids for immunotherapy against birch pollen allergy have been presented in Hamburg (Germany) during the annual EAACI congress. These studies include the first phase 3 results showing their safety and efficacy.
More info
EAACI Hybrid Congress 2023
June 2023
INMUNOTEK has participated in the commercial exhibition of the annual EAACI congress that has taken place in Hamburg (Germany). Although the hybrid character of the congress has been maintained, an important number of participants have followed it in person and have approached INMUNOTEK's stand to obtain information about its products.
More info







